Articulo de referencia

Mean kinetic temperature

In the pharmaceutical industry , Mean kinetic temperature ( MKT ) is a calculated temperature that represents the equivalent thermal effect of temperature variations over time, ...

In the pharmaceutical industry, Mean kinetic temperature (MKT) is a calculated temperature that represents the equivalent thermal effect of temperature variations over time, such that the degradation occurring under fluctuating conditions is equal to that which would occur at a constant MKT value.[1]

The mean kinetic temperature can be expressed as:

TK=ΔHRln(t1e(ΔHRT1)+t2e(ΔHRT2)++tne(ΔHRTn)t1+t2++tn){\displaystyle T_{K}={\cfrac {\frac {\Delta H}{R}}{-\ln \left({\frac {{t_{1}}e^{\left({\frac {-\Delta H}{RT_{1}}}\right)}+{t_{2}}e^{\left({\frac {-\Delta H}{RT_{2}}}\right)}+\cdots +{t_{n}}e^{\left({\frac {-\Delta H}{RT_{n}}}\right)}}{{t_{1}}+{t_{2}}+\cdots +{t_{n}}}}\right)}}}

Where:

TK{\displaystyle T_{K}\,\!} is the mean kinetic temperature in kelvins
ΔH{\displaystyle \Delta H\,\!} is the activation energy (in kJ mol−1)
R{\displaystyle R\,\!} is the gas constant (in J mol−1 K−1)
T1{\displaystyle T_{1}\,\!} to Tn{\displaystyle T_{n}\,\!} are the temperatures at each of the sample points in kelvins
t1{\displaystyle t_{1}\,\!} to tn{\displaystyle t_{n}\,\!} are time intervals at each of the sample points

When the temperature readings are taken at the same interval (i.e., t1{\displaystyle t_{1}\,\!} = t2{\displaystyle t_{2}\,\!} = {\displaystyle \cdots } = tn{\displaystyle t_{n}\,\!}), the above equation is reduced to:

TK=ΔHRln(e(ΔHRT1)+e(ΔHRT2)++e(ΔHRTn)n){\displaystyle T_{K}={\cfrac {\frac {\Delta H}{R}}{-\ln \left({\frac {e^{\left({\frac {-\Delta H}{RT_{1}}}\right)}+e^{\left({\frac {-\Delta H}{RT_{2}}}\right)}+\cdots +e^{\left({\frac {-\Delta H}{RT_{n}}}\right)}}{n}}\right)}}}

Where:

n{\displaystyle n\,\!} is the number of temperature sample points

References

  1. Jenkins, David; Cancel, Aida; Layloff, Thomas (2022). "Mean kinetic temperature evaluations through simulated temperature excursions and risk assessment with oral dosage usage for health programs". BMC Public Health. 22 (1): 300. doi:10.1186/s12889-022-12660-9. PMC 8842539.